2023/02/02 08:07:01 | |
---|---|
Price | |
16.30 EUR | |
Difference | 0.00% (0.00) |
ISIN | GB00BN7SWP63 |
Symbol | GSK |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 64,839 EUR |
Benchmark | FTSE 100 |
Bid (Bid size) | 16.30 EUR (400) |
Ask (Ask size) | 16.50 EUR (1,200) |
Open | 16.30 EUR |
High | 16.30 EUR |
Low | 16.30 EUR |
Close (prev. day) | 16.30 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | 27 |
Related Options | - |
Date | Headline | Download | |
2023/01/30 |
![]() |
Global Equity Ratings |
![]() |
2023/01/09 |
![]() |
Global Equity Ratings |
![]() |
2022/12/19 |
![]() |
Global Equity Ratings |
![]() |
2022/11/28 |
![]() |
Global Equity Ratings |
![]() |
2022/11/18 |
![]() |
Global Equity Ratings |
![]() |
2023/02/02 08:07:01 | |
---|---|
Price | |
16.30 EUR | |
Difference | 0.00% (0.00) |
ISIN | GB00BN7SWP63 |
Symbol | GSK |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 64,839 EUR |
Benchmark | FTSE 100 |
Bid (Bid size) | 16.30 EUR (400) |
Ask (Ask size) | 16.50 EUR (1,200) |
Open | 16.30 EUR |
High | 16.30 EUR |
Low | 16.30 EUR |
Close (prev. day) | 16.30 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -19.96% | -34.60% | -38.88% |
Perf (abs.) | -4.07 | -8.63 | -10.37 |
Beta | 0.60 | 0.67 | 0.65 |
Volatility | 29.62 | 37.29 | 30.20 |
Ø price 5 days | Ø volume 5 days (pcs.) | 16.25 EUR (2,173) |
Ø price 30 days | Ø volume 30 days (pcs.) | 16.35 EUR (1,463) |
Ø price 100 days | Ø volume 100 days (pcs.) | 16.18 EUR (1,438) |
Ø price 250 days | Ø volume 250 days (pcs.) | 20.43 EUR (1,533) |
YTD High | date | 16.84 EUR (2023/01/04) |
YTD Low | date | 15.82 EUR (2023/01/25) |
52 Weeks High | date | 27.09 EUR (2022/04/29) |
52 Weeks Low | date | 14.52 EUR (2022/09/26) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2023/02/01 | 17:35 | 16.18 EUR | 2.82 | 341 |
Tradegate | 2023/02/02 | 08:06 | 16.50 EUR | 0.02 | 3 |
Stuttgart | 2023/02/02 | 08:07 | 16.30 EUR | 0.00 | 1 |
SIX Swiss Exchange | 2020/04/21 | 17:36 | 21.50 CHF | 0.00 | 1 |
Munich | 2023/02/02 | 08:10 | 16.40 EUR | 0.00 | 1 |
London Stock Exchange | 2023/02/01 | 17:35 | 1,419.60 GBp | 9,892.76 | 14,460 |
Hanover | 2023/02/02 | 08:06 | 16.40 EUR | 0.00 | 1 |
Hamburg | 2023/02/02 | 08:06 | 16.40 EUR | 0.00 | 1 |
Frankfurt | 2023/02/02 | 08:01 | 16.16 EUR | 0.01 | 1 |
FINRA other OTC Issues | 2023/02/01 | 20:28 | 17.40 USD | 0.01 | 3 |
Duesseldorf | 2023/02/02 | 08:12 | 16.34 EUR | 0.00 | 1 |
Berlin | 2023/02/02 | 08:16 | 16.40 EUR | 0.00 | 1 |
BX Swiss | 2023/01/24 | 18:00 | 15.993 CHF | 0.00 | 1 |
GSK PLC |
- - |
980 Great West Road - TW8 9GS Middlesex |
Telefon: 44-20-8047-5000 |
Fax: 44-20-8047-7807 |
E-mail: - |
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom. |
Emma Walmsley | Chairman of Managing Board |
Anne-Marie Martin | Member of Executive Committee |
Christopher Corsico | Member of Executive Committee |
Jon Ellis | Member of Executive Committee |
Kapila Ratnam | Member of Executive Committee |
Neil Barnes | Member of Executive Committee |
Amy Altshul | Member of Executive Committee |
Anita Kidgell | Member of Executive Committee |
Brian McNamara | Member of Executive Committee |
Claire Lund | Member of Executive Committee |
David Redfern | Member of Executive Committee |
Deborah Waterhouse | Member of Executive Committee |
Diana Conrad | Member of Executive Committee |
Dipal Patel | Member of Executive Committee |
James Ford | Member of Executive Committee |
Kevin Sin | Member of Executive Committee |
Luke Miels | Member of Executive Committee |
Marc Jones | Member of Executive Committee |
María Cristina de Luna Basagoiti | Member of Executive Committee |
Maya Martinez-Davis | Member of Executive Committee |
Philip Thomson | Member of Executive Committee |
Regis Jean-Pierre Simard | Member of Executive Committee |
Roger Connor | Member of Executive Committee |
Sarah-Jane Hall | Member of Executive Committee |
Shobie Ramakrishnan | Member of Executive Committee |
Jonathan Symonds | Chairman of Supervisory Board |
Anne Beal | Member of Supervisory Board |
Hal Barron | Member of Supervisory Board |
Harry Dietz | Member of Supervisory Board |
Jesse Goodman | Member of Supervisory Board |
Vishal Sikka | Member of Supervisory Board |
Abhishek Agrawal | Member of Supervisory Board |
Charles Bancroft | Member of Supervisory Board |
Elizabeth Anderson | Member of Supervisory Board |
Iain Mackay | Member of Supervisory Board |
Urs Rohner | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer